Partial improvement of solar urticaria after omalizumab

Previously classified into 6 types (I-VI) based on the action spectrum, solar urticaria is now divided into 2 types: type I and type II.1 Type I defines patients who have precursors located in the serum, plasma, or cutaneous tissue fluid that become photoallergens once activated by the appropriate w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2010-02, Vol.125 (2), p.490-491
Hauptverfasser:	Waibel, Kirk H., MD, Reese, Drew A., MD, Hamilton, Robert G., PhD, Devillez, Richard L., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Allergies Allergy and Immunology Anti-Allergic Agents - therapeutic use Antibodies, Anti-Idiotypic Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Drug therapy Humans Immunoglobulin E - blood Male Omalizumab Patients Photosensitivity Disorders - drug therapy Photosensitivity Disorders - etiology Photosensitivity Disorders - immunology Sunlight - adverse effects Urticaria - drug therapy Urticaria - etiology Urticaria - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Previously classified into 6 types (I-VI) based on the action spectrum, solar urticaria is now divided into 2 types: type I and type II.1 Type I defines patients who have precursors located in the serum, plasma, or cutaneous tissue fluid that become photoallergens once activated by the appropriate wavelength and bind to IgE receptors, resulting in mast cell degranulation.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2009.11.007